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Abstract: It is known that phosphoinositide-specific phospholipases g1 (PLCg1) can trigger several signalling 
pathways to regulate cell proliferation, differentiation, and metastasis. However, whether this kinase is highly 
expressive and active in human gastric adenocarcinomas, and whether it can play an important role in the de-
velopment of the cancer, have not yet been investigated. The aim of the study was to investigate the expression 
of PLCg1 in human gastric adenocarcinoma, while the question of whether PLCg1 can be activated through 
protein kinase B (Akt) signalling pathways to regulate cell migration was further explored using human gastric 
adenocarcinoma BGC-823 cell line. The expression of PLCg1 in human adenocarcinoma was detected using 
immunohistochemical staining. The BGC-823 cells were cultured and treated with inhibitors or transfected with 
plasmid construction. The cell migration of BGC-823 cells was measured with wound healing assay, cell migration 
assay, and the ruffling assay. The expression levels of PLCg1 and its related signal molecules in BGC-823 cells 
were assessed using Western blot analysis or gelatine zymography assay. PLCg1 was highly expressed in human 
gastric adenocarcinomas, especially in the region with lymph node metastasis. It was shown that migration of 
BGC-823 cells in vitro depends on PLCg1 activation. This activation is mediated through Akt, an upstream of 
PLCg1 that triggers the PLCg1/extracellular signal-regulated kinase (ERK)/matrix metalloproteinase (MMP) 
pathway in BGC-823 cells. PLCg1 activities play an important role in the metastasis of gastric adenocarcinoma, 
and may serve as a potential therapeutic target in this type of cancer. (Folia Histochemica et Cytobiologica 2014, 
Vol. 52, No. 3, 178–186)
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Introduction
It has been reported that approximately 90% of mor-
tality from cancers arises from the metastatic spread 
of primary tumors to distant sites, including gastric 
adenocarcinoma [1]. Metastasis usually includes 
a complex series of steps in which cancer cells leave 
the original tumor site and migrate to other parts of 
the body via the bloodstream, the lymphatic system, 
or by direct extension. Inhibition of any one metastatic 
step — such as migration or invasion — could prevent 
tumor dissemination [1, 2]. Recent studies suggest 
targeted molecular therapy as a potential solution in 
cancer therapy, because it is more effective than cur-
rent treatments and less harmful to normal cells [3]. 
The regulation of certain key signalling molecules 
has been identified as crucial in tumor metastasis; 
the molecules involved in cell migration may thus 
serve as molecular targets for the treatment of tumor 
metastasis [4, 5].
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Several lines of evidence indicate that phosphoino-
sitide-specific phospholipase g (PLCg) is one of key 
signalling molecules that regulates tumor metasta - 
sis [6–9]. PLCg has two isoforms, PLCg1 and PLCg2 [6, 7]. 
Activation of PLCg may occur in response to either in-
tegrin receptors or growth factor-dependent pathways 
— including epidermal growth factor (EGF) — and 
induces hydrolysis of phosphatidylinositol 4,5-bispho-
sphate (PtdIns(4,5)P2) to form the second messengers 
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate 
(IP3), which in turn activate a number of signalling 
pathways to regulate cell metabolism and cell metasta- 
sis [6–9]. For example, activated PLCg has been thought 
to play a critical role in both cytoskeletal changes and in 
the migration associated with the metastatic process in 
cancer cells [8]. Preventing the activation of the PLCg 
signalling pathway could limit the metastatic potential 
of breast and prostate cancers [9]. Both stable and in-
ducible PLCg1 downregulation resulted in an almost 
complete inhibition of breast cancer-derived experi-
mental lung metastasis formation [10]. Thus, PLCg 
plays an important role in some types of metastatic 
cancer. However, it is not clear whether the downre-
gulation of PLCg1 may play a similar role in human 
gastric adenocarcinoma, compared to other types of 
cancers, and the possible effects of its inhibition have 
yet not been explored.
In addition to PLCg, protein kinase B (PKB/Akt), 
another well-known regulator of tumor metastasis, has 
been shown to modulate the same physiological process 
in some types of cancer [11, 12]. Both PLCg and Akt are 
known to be involved in the regulation of the growth and 
migration of MDA-MB-468 breast cancer and SW480 
colon cancer cells [11]. The interaction between PLCg 
and Akt was found to regulate the G2/M transition 
in MDA-MB-231 breast cancer cells [12]. Therefore, 
exploring the relationship of PLCg and Akt in cancer 
metastasis will greatly assist in understanding the regula-
tory mechanisms of PLCg1 underpinning cell migration.
In this project, we aimed to study the expression 
level of PLCg1 in human gastric adenocarcinoma and 
normal gastric mucosa tissue, and to further investi-
gate the molecular mechanisms of the PLCg1 activity 
associated with Akt that underpins cell migration in 
the human gastric adenocarcinoma cell line, BGC- 
-823. The results of this project are intended to provi-
de additional evidence that PLCg may be a potential 
target for cancer treatment, and especially for the 
treatment of gastric adenocarcinoma.
Material and methods
Reagents and antibodies. Antibodies against PLCg1, p-PL- 
-Cg1 (Y783), p-PLCg1 (S1248), Akt, p-Akt (S473), Extracel-
lular signal-regulated kinases (ERK), p-ERK (T202/Y204), 
Matrix metalloproteinase-9 (MMP9), MMP2, Human influ-
enza haemagglutinin (HA), myc, and b-actin were purchased 
from Cell Signalling Technology, Inc. (Beverly, MA, USA) 
and Santa Cruz Biotechnology (Santa Cruz, Freemont, CA, 
USA). Inhibitors (U73122 and Triciribine) were obtained 
from Sigma-Aldrich in China (Shanghai, China). Other 
reagents were of the highest grade commercially available. 
Tissue specimens. Five fresh specimens of normal gastric 
mucosa tissue and twenty specimens of T2, T3, N0–N2 ga-
stric adenocarcinoma tissue were obtained from Zhongshan 
Hospital, Xiamen University and assessed by the Tumor 
Node Metastasis (TNM) staging system. The study proto-
col and design were approved by the Ethics Committee of 
Zhongshan Hospital, Xiamen University (ID No. 20060607). 
Each specimen underwent protein extraction and Western 
blot analysis. The tissue microarray, which includes 45 spe-
cimens of adenocarcinoma and 10 of normal gastric mucosa, 
was purchased from Biomax, Inc. (Rockville, MD, USA) 
for immunohistochemical staining. All our clinical studies 
were conducted according to the principles expressed in the 
Declaration of Helsinki.
Cell culture. The human gastric cancer cell line, BGC-823, was 
obtained from the Shanghai Institute of Cell Biology, Chinese 
Academy of Sciences, Shanghai, China, and was maintained in 
RPMI1640 medium supplemented with 10% foetal bovine se-
rum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin, 
at 37°C in a water-saturated atmosphere of 5% CO2.
Plasmid construction and transfection. Rat PLCg1 cDNA 
was N-terminally tagged with the HA sequence and subc-
loned into pRK5-HA (pRK5-HA/PLCg1). The Y783 and 
S1248 mutations were obtained by PCR (PLCg1 Y783A, 
5’CAACCCTGGTTTCGCTGTGGAGGCCAACCCTAT-
GC (forward primer), 5’TTGGCCTCCACAGCGAAAC-
CAGGGTTGCGGCC (reverse primer); PLCg1 S1248A, 
5’CCGGGAAGGGGCCTTTGAAGCCAGATACCAG-
CAG (forward primer), 5’ CTGGCTTCAAAGGCCCCT-
TCCCGGGCCCG (reverse primer). The ShPLCg1 vector 
(primer: 5’CCGGCCAGATCAGTAACCCTGAATTC-
TCGAGAATTCAGGGTTACTGATCTGTTTTTG3’) 
was purchased from Gene Chem (Shanghai, China). The 
different expression vectors of PLCg1 and myc–Akt were 
transfected into BGC-823 cells using Lipofectamine 2000, 
according to the manufacturer’s procedure (Invitrogen, 
Carlsbad, CA, USA). Briefly, BGC-823 cells were cultured 
in a 60-mm dish for 20–24 h until they reached 60–70% 
confluence. The plasmid-containing buffer was then added 
and left for 36 h, and was followed by the various experi-
mental procedures in which the expression level of PLCg1 
and Akt were detected with Western blot analysis, prior to 
the other experiments.
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Wound healing assay. The assay was conducted according 
to published protocol [13]. Briefly, a total of 2 × 106 cells 
were seeded onto two six-well plates and allowed to reach 
full confluence. Two centrelines were marked on the 
upside of each well along its horizontal axis, to designate 
the loci at which images would be acquired at each time 
point. Vertical linear scratches were introduced into the 
cell monolayers using a 10 μL sterile pipette tip. Each well 
received 2 scratches. Culture plates were washed with PBS 
and incubated with PLCg inhibitor U73122, which was fol-
lowed by EGF treatment in serum-free medium. Images at 
40 × magnification were acquired at 0, 7, 24, and 48 h after 
scratching at each intersection of the scratch wound (vertical 
defect). For each time point, 4 measurements were taken 
per well in each of 3 wells, and the average of the horizontal 
width of the linear defect in pixels was calculated using the 
Image-Pro Plus 6.0 system. The mean percentage closure 
was calculated by compared with time 0.
Cell migration assay. Cell migration was performed in Tran-
swell chambers (tissue culture treated, 6.5 mm diameter, 
8 μm pores, Corning Inc., Corning, NY, USA) as described 
elsewhere [14]. Briefly, 2 × 104 cells in serum-free DMEM 
were placed into the upper chambers of Transwell inserts 
set within wells with 8 μm pore filters, and incubated at 37°C 
for 12 h. Cells on the upper surface of the chambers were 
then removed with cotton swabs. The migrated cells on the 
lower membrane surface were fixed in methanol and stained 
with 0.1% Giemsa stain. Eight microscope fields (× 200) 
from each Transwell chamber were randomly selected, and 
cells adhering to the undersurface of the filter were imaged 
and counted using an Olympus BX41 microscope equipped 
with a digital camera (Olympus, Tokyo, Japan).
Gelatine zymography assay. The assay was conducted accor-
ding to published protocol [15]. Protein concentrations in the 
conditioned media were determined using the bicinchoninic 
acid method (BCA kit) (Pierce, Rockford, IL, USA). The 
conditioned media were mixed with an equal volume of 
4 × sample buffer (200 mM Tris-HCl, 8% SDS, 0.4% bro-
mophenol blue, 40% glycerol) and electrophoresed on 6% 
SDS polyacrylamide gels containing 1 mg/ml of gelatine (Bio 
Basic Inc., Markham, Ontario, Canada). The gels were then 
washed twice for 30 min in 2.5% Triton X-100 at room tem-
perature, and incubated for 48 h at 37°C in incubation buffer 
(50 mM Tris-HCl (pH 7.5), 5 mM CaCl2, 150 mM NaCl, 1 μM 
ZnCl2, and 0.2% Brij35). Gels were then stained for 1 h with 
0.25% (w/v) Coomassie brilliant blue R-250, and de-stained 
in de-staining buffer (10% acetic acid and 50% methanol).
Confocal microscopy and ruffling assay. The assay was con-
ducted according to published protocol [10]. The cells were 
seeded on glass coverslips in 6-well plates and pretreated 
with U73122, followed by EGF treatment. The treated cells 
were rinsed with PBS once and fixed in 4% paraformalde-
hyde for 10 min, and then washed three times with PBS. 
After 5 min permeation with 0.5% Triton X-100, the cells 
were incubated with Rhodamine-conjugated Phalloidin 
(Cytoskeleton Inc., Denver, CO, USA) for 30 min at room 
temperature, before being stained with DAPI for 30 sec. 
Finally, the cells were observed and photographed using 
confocal microscopy.
Western blot analysis. The protein extracts were subjected to 
SDS-PAGE (8–10%) and transferred to nitrocellulose mem-
brane for Western blot analysis [16]. The membrane was in-
cubated at 4°C overnight with various antibodies as required, 
which was followed by the addition of the corresponding 
secondary antibody at room temperature for 1 to 2 h. An ECL 
kit was used to detect antibody reactivity (Pierce). 
Immunohistochemical staining and analysis. The immu-
nohistochemistry was performed as described previously [17, 
18]. The tissue microarray was deparaffinised in xylene and 
rehydrated in graded alcohols and distilled water. Following 
antigen retrieval using the Citrate Buffer method — which 
can enhance the staining intensity of the antibodies by 
unmasking the antigens and epitopes in formalin-fixed and 
paraffin-embedded tissue sections — endogenous peroxi-
dase activity was blocked with 3% hydrogen peroxide in 
methanol for 10 min at room temperature. This was followed 
by rehydration in PBS and incubation with 10% goat serum 
for 10 min to bind nonspecific antigens. As described in the 
manufacturer’s instruction (MAIXIN.BIO, Fuzhou, China), 
the sections were incubated overnight at 4°C with PLCg1 
(1:100 dilutions) primary antibody and subsequently with 
secondary antibody (1:400) for 60 min at room temperature. 
Diaminobenzidine (DAB) was used to visualize the im-
munohistochemical reaction, before counterstaining with 
haematoxylin. In the control sections, the specific primary 
antibody was omitted or replaced with non-immune serum 
or isotype-matched immunoglobulins. Photomicrographs 
were taken using an Olympus BX41 microscope equipped 
with a digital camera.
A semiquantitative scoring system based on staining 
intensity and the distribution of positive cells was used to 
evaluate PLCg1 expression [18, 19]. The intensity of PLCg1 
staining ranged from 0 to 3 — i.e., negative (–), weak (+), 
moderate (++) , and strong (+++), and was performed 
using Image-Pro Plus 6.0 Software. Two pathologists were 
consulted for agreement and the scores were quantified by 
three independent observers using the criteria for statistical 
analysis detailed in Figure 1C. 
Statistical analysis. The differences between the groups 
were examined for statistical significance using the c2 test, 
Student’s t-test, and one-way ANOVA using SPSS software. 
A value of p < 0.05 was considered significant.
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PLCg1 is highly expressed in human  
gastric adenocarcinoma
Fresh human normal gastric mucosa tissue and gastric 
adenocarcinoma tissue were used for Western blot 
analysis of PLCg1. The results showed that PLCg1 
expression was higher in human gastric adenocarci-
noma than in normal gastric mucosa, while homo-
genously weak expression of PLCg1 was observed in 
normal gastric mucosa tissues (Figure 1A). Simulta-
neously, PLCg1 expression was higher in gastric ade-
Figure 1. PLCg1 is highly expressed in gastric adenocarcinoma with regional lymph node metastasis. A. PLCg1 expression 
in fresh human gastric adenocarcinoma and normal gastric mucosa tissues was detected using Western blot analysis with 
anti-PLCg1 and b-actin antibodies; B. PLCg1 expression in gastric adenocarcinoma and normal gastric mucosa tissues 
was detected in the tissue assay with immunohistochemical staining as described in the Material and methods section 
(magnification × 400); C. Criteria for statistical analysis of PLCg1 expression in gastric adenocarcinoma tissues. PLCg1 
expression in gastric adenocarcinoma tissues was detected in the tissue assay with immunohistochemical staining, as de-
scribed in the Material and methods section (magnification × 200)
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nocarcinoma tissues with lymph node metastasis (N1, 
N2) than in gastric adenocarcinoma tissues lacking 
lymph node metastasis (N0) (Figure 1A). 
Subsequently, PLCg1 expression was assessed 
immunohistochemically on a tissue microarray. The 
majority (86%) of gastric adenocarcinoma specimens 
(T2, T3, T4) showed a specific immune reactivity to 
PLCg1 (Figure 1B and 1C, Table 1, p < 0.01). PLCg1 
expression was significantly higher in gastric adeno-
carcinoma specimens with regional lymph node meta-
stasis (N1, N2) than in non-metastatic specimens (N0) 
(Figure 1C, Table 1, p < 0.05). These data indicate 
that PLCg1 expression is higher in gastric adenocar-
cinoma tissues than in normal gastric mucosa, and, 
specifically, in gastric adenocarcinoma tissues with 
regional lymph node metastasis. 
The migration of gastric adenocarcinoma cells 
partly depends on PLCg1 activation 
To investigate the role of PLCg1 in the migration of 
gastric adenocarcinoma cells, cells of the cultured 
gastric adenocarcinoma line BGC-823 were pretre-
ated using PLCg1 inhibitor U73122 (5 μmol/L) for 
the indicated time in the presence or absence of EGF 
(20 ng/ml) [20, 21]. This was followed by a wound 
healing assay and Western blot analysis. The result of 
the wound healing assay showed that the addition of 
U73122 significantly suppressed the mean percentage 
closure of BGC-823 cells in the presence or absence of 
EGF treatment, compared with the untreated group, 
while the inhibitory effect of U73122 on the mean 
percentage closure of BGC-823 cells increased in 
a time-dependent manner (Figure 2A). 
Simultaneously, Western blot analysis showed 
that the addition of PLCg1 inhibitor U73122 redu-
ced the phosphorylation level of PLCg1 at the Y783 
site (p-PLCg1 (Y783)), which is essential for PLCg1 
activation [3], with a decrease in the expression level 
of MMP9 and MMP2 in the presence or absence of 
EGF treatment (Figure 2B). 
Since several lines of evidence indicate that the 
PLCg1 substrate PtdIns(4, 5)P2 and the enzyme itself 
were involved in cytoskeletal rearrangement through 
the modulation of actin-binding proteins [22, 23], we 
tested the effects of U73122 on actin cytoskeleton 
using confocal microscopy and a ruffling assay after 
rhodamine-conjugated phalloidin staining. The 
addition of U73122 led to a marked decrease in the 
number of membrane ruffles of BGC-823 cells in 
the presence or absence of EGF treatment (Figure 
2C), with the reduction of actin cytoskeleton reorga-
nization in cytoplasm (Figure 2D, indicated as white 
arrows). Taken together, these data suggest that the 
migration of BGC-823 cells partly depends on PLCg1 
activation.
Akt is involved in PLCg1-dependent migration  
of gastric adenocarcinoma cells
To confirm the role of Akt in PLCg1-dependent 
migration of gastric adenocarcinoma cells, BGC-823 
cells were treated with an Akt inhibitor Triciribine 
(TCN) for the indicated time, and PLCg1 expression 
and activation were assessed by Western blot analysis. 
The addition of TCN (10 μmol/L) significantly 
suppressed PLCg1 and Akt activation, with a slight 
downregulation of total PLCg1 expression (Figure 
3A). Similar results were observed in BGC-823 cells 
with the transfection of the myc–Akt vector. Over-
expression of Akt upregulated the expression level of 
PLCg1 and its activation (p-PLCg1 (Y783)), while the 
expression of p-PLCg1 (S1248) was also upregulated, 
albeit to a lower extent (Figure 3B). Simultaneously, 
overexpression of Akt upregulated the expression 
level of MMP2/9 (Figure 3B). 
Interestingly, the phosphorylation level of ERK 
(p-ERK) also was upregulated in the BGC-823 cells 
transfected with overexpression of the Akt vector (Fi-
gure 3B). EGF treatment enhanced the effect of Akt 
on p-PLCg1 (Y783), p-PLCg1 (S1248), p-ERK, and 
MMP2/9 expression. Furthermore, only HA-PLCg1 
Table 1. Clinical pathological characteristics of PLCg1 in gastric adenocarcinoma
PLCg1
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Figure 2. The migration of BGC-823 cells partly depends on PLCg1 activation. A. Cells were treated with or without 
U73122 (5 μmol/L) for the indicated time in the presence or absence of EGF (20 ng/ml); this was followed by wound he-
aling assays, as described in the Material and methods section (magnification × 40); B. Cells were pretreated with U73122 
(5 μmol/L) for 2 h, and then treated with EGF (20 ng/ml) for 0.5 h. Protein expressions of p-PLCg1 (Y783), MMP2, 
MMP9, and b-actin were detected using Western blot analysis with the corresponding antibodies; C. Cells were pretre-
ated with U73122 (5 μmol/L) for 2 h and then treated with EGF (20 ng/ml) for 1 h. The formation of membrane ruffles 
was then detected using confocal microscopy and ruffling assay following Rhodamine-conjugated Phalloidin staining, as 
described in the Material and methods section (magnification × 400, *p < 0.05, **p < 0.01, and ***p < 0.001); D. Cells 
were treated as in Figure 2C, and the effect of U73122 on actin cytoskeleton was observed using confocal microscopy 
following Rhodamine-conjugated Phalloidin staining. The white arrows indicate the actin aggregation (magnification × 800). 
The data are representative of three or five independent experiments, each yielding similar results
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Figure 3. PLCg1-dependent cell migration is related to Akt expression in BGC-823 cells. A. Cells were treated with TCN 
(10 μmol/L) for the indicated time; the protein expression of PLCg1, p-PLCg1 (Y783), Akt, p-Akt (S473), and b-actin 
was then detected using Western blot analysis with the corresponding antibodies; B. The myc–Akt vector was transfected 
into cells and followed by treatment with EGF (20 ng/ml) for 0.5 h; the protein expression of PLCg1, p-PLCg1 (Y783), 
p-PLCg1 (S1248), ERK, p-ERK1/2 (T202/Y204), MMP2, MMP3, Akt, myc, and b-actin was then detected using Western 
blot analysis with the corresponding antibodies; C. HA-PLCg1, HA-PLCg1 Y783A, and HA-PLCg1 S1248A vectors 
were transfected into cells, and the protein expression of PLCg1, p-PLCg1 (Y783), p-PLCg1 (S1248), ERK, p-ERK1/2 
(T202/Y204), HA, and b-actin was detected using Western blot analysis with the corresponding antibodies; D. Cells were 
transfected with HA-PLCg1 and HA-PLCg1 Y783A vectors; this was followed by the gelatine zymography assay described 
in the Material and methods section; E. Cells were transfected with ShPLCg1 vector; this was followed by the Transwell 
assay described in the Material and methods section (***p < 0.001). The data are representative of three or five indepen-
dent experiments, each yielding similar results
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Y783A significantly reduced the expression level of 
p-ERK in BGC-823 cells transfected with HA-PLCg1, 
HA-PLCg1 Y783A, and HA-PLCg1 S1248A vectors, 
showing that PLCg1 activation (p-PLCg1 (Y783)) was 
required for ERK phosphorylation in BGC-823 cells 
(Figure 3C). 
At the same time, HA-PLCg1 Y783A significantly 
reduced the expression of MMP2/9, as seen using 
gelatine zymography assay (Figure 3D), and the 
results of the Transwell assay demonstrated that the 
transfection of ShPLCg1 vector into the BGC-823 
cells reduced the number of cell migrations (Figure 
3E, ***p < 0.001). Therefore, the data indicate the 
involvement of Akt in PLCg1-dependent migration 
of gastric adenocarcinoma cells, in which Akt triggers 
the PLCg/ERK/MMP pathway.
Discussion
In this study, we demonstrated that PLCg1 expression 
was related to the dissemination of gastric adenocarci-
noma. Both the migration of cells and reorganization 
of the actin cytoskeleton partly depended on PLCg1 
activation in the BGC-823 gastric adenocarcinoma 
cell line. This activation was mediated through Akt, an 
upstream of PLCg1 that triggered PLCg1/ERK/MMP 
pathway in the BGC-823 cells. Thus, PLCg1 activities 
may play an important role in the dissemination of 
gastric adenocarcinoma cells.
As one of switches that triggers cell migration, 
PLCg1 appears to be at the convergence point of va-
rious signalling pathways leading to cell cytoskeleton 
rearrangement and motility [24]. In line with previous 
studies of other tumors [8–10, 25], the data from 
the tissue microarray and human tumor specimens 
demonstrate that PLCg1 expression is related to 
the dissemination of gastric adenocarcinoma cells. 
Furthermore, the disruption of PLCg1 led to the at-
tenuation of cell migration and a decrease in both the 
number of cell membrane ruffles and the incidence 
of actin reorganization in BGC-823 cells. Thus, the 
migration of gastric adenocarcinoma cells partly 
depends on PLCg1 activation, and blocking PLCg1 
could be a potential therapeutic approach to prevent 
gastric adenocarcinoma metastasis. 
Although several lines of evidence indicated that 
the interaction between Akt and PLCg is involved 
in cell growth and migration [11, 12], some studies 
argued against the regulatory mechanisms of the two 
signalling pathways in this process, whether upstream, 
downstream, or with each other. Browaeys-Poly et al. 
reported that Akt was known to phosphorylate its sub-
strate, PLCg, and then to regulate the G2/M transition 
triggered by FGF receptors in MDA-MB-231 breast 
cancer cells [12]. However, Li et al. observed that Akt 
was phosphorylated to stimulate cell proliferation 
through the activated PLCg/PKCg/Src/PI3K pathway 
in EGF-stimulated rat and human conjunctival goblet 
cells [26]. Our data, indicating that Akt phosphoryla-
tes PLCg1 at the Y783 site and promotes cell migra-
tion, is consistent with Browaeys-Poly’s study [12]. The 
different regulatory mechanisms of the two signalling 
pathways might be dependent on cellular context and 
type. Previous studies found that the PLCg1 activation 
was also regulated by phosphorylation at an additional 
serine/threonine site, even though PLCg1 was activa-
ted by tyrosine phosphorylation [27, 28]. Likewise, Akt 
simultaneously phosphorylates PLCg1 at the Y783 
and S1248 sites in BGC-823 cells. We thus suggest 
that Akt, as an upstream, interacts with PLCg1, acti-
vates PLCg1 at the Y783 and S1248 sites in BGC-823 
cells, and is involved in PLCg1-dependent migration. 
Further investigation into the role of p-PLCg1 (S1248) 
phosphorylated by Akt in gastric adenocarcinoma cell 
migration is underway.
In addition, ERK1/2, as a downstream effect 
of PLCg1, has been described as regulating MMP 
expression [29, 30]. The association of Ras-GRF1/2 
with PLCg1 enables PLCg1 to be recruited to focal 
adhesions and is required for Ras signalling, ERK ac-
tivation, and MMP-3 release downstream of IL-1 sti-
mulation [29]. It was shown that PLCg1 could activate 
ERK1/2 through the PLCg1-PKCg-B-Raf pathway in 
VEGF-treated endothelial cells [30]. Consistent with 
previous studies, our data also indicate that PLCg1 
activation is required for the phosphorylation of ERK. 
Combined with our result that the phosphorylation of 
ERK increases with the transfection of the myc–Akt 
vector in the presence or absence of EGF treatment, 
we suggest that Akt could mediate PLCg1 activation, 
which would trigger the PLCg1/ERK/MMP pathway 
to modulate the migration of BGC-823 cells.
In summary, in this study we have shown that 
PLCg1 activation is partly required for the migration 
of gastric adenocarcinoma cells. Moreover, this Akt-
-mediated activation triggers the PLCg1/ERK/MMP 
pathway in BGC-823 cells. Thus, the activation of 
PLCg1 and its interaction with Akt underline PLCg1 
as a potential therapeutic target in gastric adenocar-
cinoma.
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